NYSE:ABBVBiotechs
Should AbbVie’s (ABBV) Immunology Strength and Raised Outlook Offset Earnings Dip for Investors?
In the first quarter of 2026, AbbVie reported revenue rising to US$15,002 million from US$13,343 million a year earlier, while net income fell to US$695 million and diluted EPS from continuing operations declined to US$0.39 from US$0.72.
Alongside the earnings beat, AbbVie highlighted strong momentum from immunology drugs Skyrizi and Rinvoq, which helped offset ongoing pressure from legacy product Humira and underpinned a higher full‑year adjusted earnings outlook.
We’ll now examine how...